Following a full submission:
vildagliptin (Galvus) is accepted for restricted use within NHS Scotland.
Indication under review: treatment of type 2 diabetes mellitus in adults as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
SMC restriction: for use in patients for whom both metformin and sulphonylureas are inappropriate due to contraindications or intolerance.
In two comparator controlled studies the non-inferiority of vildagliptin to first-line oral anti-diabetic agents was not shown. A network meta-analysis demonstrated similar reductions in HbA1c at 24 weeks for vildagliptin versus another dipeptidyl peptidase 4 (DPP-4) inhibitor.
|Drug Name:||vildagliptin (Galvus)|
|SMC Drug ID:||826/12|
|Manufacturer:||Novartis Pharmaceuticals UK Ltd|
|Indication:||As monotherapy, in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.|
|Sub Category:||6.1 Drugs used in diabetes|
|Submission Type:||Full submission|
|Date Advice Published:||14 January 2013|